"Designing Growth Strategies is in our DNA"

Tardive Dyskinesia Therapeutics Market Size, Share & Industry Analysis, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: February 23, 2026 | Format: PDF | Report ID: FBI107532

 


To get information on various segments, share your queries with us

  ATTRIBUTE

  DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 9.10% from 2026 to 2034

Unit

Value (USD billion)

Segmentation

By Drug, Distribution Channel, and Region

By Drug

  • Deutetrabenazine
  • Valbenazine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • U.S. (By Drug, By Distribution Channel)
  • Europe (By Drug, By Distribution Channel, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Drug, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Drug, By Distribution Channel)
  • 2021-2034
  • 2025
  • 2021-2024
  • 101
Download Free Sample

    man icon
    Mail icon

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann